Stockreport

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

CG Oncology, Inc. - Common stock  (CGON) 
PDF Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladde [Read more]